



NEWS RELEASE

Arcus Biosciences to Present at the Jefferies 2019 Global Healthcare Conference

5/21/2019

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that Terry Rosen, Ph.D., Chief Executive Officer, will present at the Jefferies 2019 Global Healthcare Conference on Tuesday, June 4, 2019 at 4 pm ET at the Grand Hyatt, in New York, NY.

To access the live audio webcast of the presentation, please visit the "Investors" section of the Arcus website at www.arcusbio.com. A replay of the webcast will be available for 30 days following the live event.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist AB928, which is in a Phase 1/1b program to evaluate AB928 in combination with other agents in multiple tumor types, and an anti-PD-1 antibody AB122, which is being evaluated in a Phase 1 trial and is being tested in combination with Arcus's other product candidates. Arcus's other programs include AB154, an anti-TIGIT antibody, which is in a Phase 1 trial to evaluate AB154 as monotherapy and in combination with AB122, and AB680, a small molecule inhibitor of CD73, which is in a Phase 1 healthy volunteer study. Arcus has extensive in-house expertise in medicinal chemistry, immunology, biochemistry, pharmacology and structural biology. For more information about Arcus Biosciences, please visit www.arcusbio.com.

Source: Arcus Biosciences

View source version on **businesswire.com**: <https://www.businesswire.com/news/home/20190521005716/en/>

Katherine Bock

(415) 533-5670

kbock@arcusbio.com

Nicole Arndt

(510) 284-4728

narndt@arcusbio.com

Source: Arcus Biosciences, Inc.